Small doses of Sedatives May Exacerbate Focal Neurologic Deficits

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003774

Enrollment

Unknown

Registered

2013-10-10

Start date

2013-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supratentorial Tumor

Interventions

Propofol:Propofol Administer

Midazolam:Midazolam Administer

Fentanyl:Fentanyl Administer

Dexmedetomidine:Dexmedetomidine Administer

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Supratentorial mass lesion (frontal-parietal-temporal regions); Elective craniotomy; Aged 18 to 65; ASA I-2; Institutional approval and informed consent.

Exclusion criteria

Exclusion criteria: Unable to comprehend and cooperate with the neurologic examination; Impaired mental status; Taking sedative drugs in the past 24 hours ; Taking pain reliever in the past 24 hours; Drug and/or alcohol abuse; Preganant and/or lactation period woman; Recurrent brian tumor

Design outcomes

Primary

Measure	Time frame
NIH Stoke Scale;	—

Countries

China

Contacts

Public ContactAdrian Gelb

gelba@anesthesia.ucsf.edu+1 415 476-0121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026